Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024GlobeNewsWire • 07/30/24
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying WarrantsGlobeNewsWire • 05/24/24
Genelux Corporation Announces Proposed Public Offering of Common Stock and WarrantsGlobeNewsWire • 05/23/24
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business UpdatesGlobeNewsWire • 05/09/24
Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a TurnaroundZacks Investment Research • 04/26/24
Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a TurnaroundZacks Investment Research • 04/23/24
After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)Zacks Investment Research • 04/05/24
All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to BuyZacks Investment Research • 04/04/24
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 04/01/24
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian CancerGlobeNewsWire • 11/27/23
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesGlobeNewsWire • 11/14/23
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/14/23
Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage TestingSeeking Alpha • 08/30/23
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business UpdatesGlobeNewsWire • 08/14/23
Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023GlobeNewsWire • 08/02/23
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New HiresGlobeNewsWire • 07/20/23
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in ImmunologyGlobeNewsWire • 07/10/23
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLCGlobeNewsWire • 06/29/23
Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023GlobeNewsWire • 06/22/23
Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) OnGlobeNewsWire • 05/25/23